Category: Interpretational.com

Lob’s New API Feature Increases Deliverability for Direct Mail

Press release content from Business Wire. The AP news staff was not involved in its creation. https://apnews.com/press-release/business-wire/technology-business-north-america-san-francisco-industrial-products-and-services-efc0d308c0c546f8b14f806bbdb574c2 Click to copy SAN FRANCISCO–(BUSINESS WIRE)–Dec 9, 2020– Lob, the direct mail automation company, today announced the Lob Confidence Score, a new API feature that assesses mail deliverability. The Lob Confidence Score helps companies answer the question of “will my mail actually arrive...

READ MORE Lob’s New API Feature Increases Deliverability for Direct Mail

Another Vote of ‘Confidence’ – a Summary of the Moderna COVID-19 vaccine results

Written by PHASTAR on 16 November 2020. Posted in Blog Another Monday, another COVID-19 vaccine trial delivering some positive news. This week it is Moderna who have announced the results[1] from their first interim analysis, and the numbers are just as impressive as those released by Pfizer and BioNTech last week and discussed here[2]. We also have some actual numbers...

READ MORE Another Vote of ‘Confidence’ – a Summary of the Moderna COVID-19 vaccine results

About confidence intervals for the Biontech/Pfizer Covid-19 vaccine candidate

Probably, many of you have read the positive news from the Biontech/Pfizer press release[1] from November 9th: “Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis” Not being a biostatistician, I was curious how vaccine efficacy is exactly measured. Also, how does...

READ MORE About confidence intervals for the Biontech/Pfizer Covid-19 vaccine candidate

Seagen and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer

BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)–Oct 12, 2020– Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial known as EV-201. The cohort is evaluating the antibody-drug conjugate PADCEV ® (enfortumab vedotin-ejfv) for patients with locally...

READ MORE Seagen and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer

Generated by Feedzy